BioCentury
ARTICLE | Distillery Therapeutics

Dermatology

May 9, 2018 3:16 PM UTC

Mouse and cell culture studies suggest RHBDF2 inhibition or sulforaphane could help treat palmoplantar keratoderma. In a mouse model of palmoplantar keratoderma of the footpad, knockout of RHBDF2 decreased footpad epidermis thickness compared with normal RHBDF2 expression. In RHBDF2-mutant keratinocytes derived from patients with diffuse epidermolytic palmoplantar keratoderma (tylosis), the antioxidant sulforaphane decreased levels of RHBDF2, proliferation, inflammation and reaction oxygen species (ROS) markers compared with vehicle. Next steps could include testing sulforaphane in mouse models of other types of palmoplantar keratoderma and other diseases involving hyperproliferative keratinocytes...

BCIQ Company Profiles

Queen Mary University of London

BCIQ Target Profiles

Rhomboid 5 homolog 2 (RHBDF2)